Effect of lurasidone plus sulpiride on treatment efficacy, psychiatric manifestations, and quality of life among patients with schizophrenia

Table 4 Psychiatric symptom assessment of the two patient groups

Indicators	Control group (n = 50)	Observation group (n = 60)	t value	P value
Positive symptoms
Before treatment	23.24 ± 6.22	21.22 ± 7.68	1.495	0.138
After treatment	14.46 ± 2.92a	10.92 ± 2.63b	6.685	< 0.001
Negative symptoms
Before treatment	29.86 ± 10.60	30.42 ± 7.84	0.318	0.751
After treatment	25.00 ± 5.41a	18.78 ± 5.48b	5.962	< 0.001
General psychopathological symptoms
Before treatment	60.26 ± 13.15	61.33 ± 13.50	0.121	0.904
After treatment	43.68 ± 12.99a	35.95 ± 10.46b	3.457	< 0.001

^aP < 0.05, between the same groups compared with before treatment.

^bP < 0.01, between the same groups compared with before treatment.